AAPS Elevates Eight Members to Fellow Status

Fellows Program Recognizes Scientific Impact, Leadership, and Service

Arlington, VA—AAPS is pleased to announce that eight members have been selected for elevation to Fellow status in recognition of their professional excellence and sustained superior impact in fields relevant to AAPS’ mission: advancing the capacity of pharmaceutical scientists to develop products and therapies that improve global health.
The new Fellows will be formally inducted before the membership at PharmSci 360 on Sunday, October 20.

AAPS Fellows are nominated by AAPS members. The status of Fellow denotes professional excellence and a sustained, positive impact on global health and the AAPS community.

“It has been inspiring to review the nomination packages, and celebrate the creativity and passion shown by these researchers as well as learn more about their many scientific accomplishments,” AAPS 2024 Fellows Committee Chair Joan Korth-Bradley, Pharm.D., Ph.D., FAAPS, said. “I would like to acknowledge the care taken by those who prepared the nominations, as well as the members of the AAPS staff who performed the initial screening review and members of the 2024 Fellows Committee who carried out their own reviews before coming together and discussing the nomination packages together.
“Our newest Fellows will be recognized at PharmSci 360 in Salt Lake City. I look forward to celebrating their achievement with them.”

“These eight individuals exemplify the spirt of pharmaceutical science,” 2024 AAPS President Gopi Shankar, Ph.D., M.B.A., FAAPS, said. “Their scientific leadership has led to advancements in support of patients worldwide across multiple disciplines. I am honored to share the stage with them at PharmSci 360 in October.”

The following AAPS members have been elevated to Fellow in 2024.

Nagesh Bandi, Ph.D., FAAPS
Nagesh Bandi, Ph.D., is recognized for his transformative impact in the international regulatory CMC community, including the development of a technical/regulatory framework for risk-based biopharmaceutics; abuse deterrent formulations (ADF) testing and labelling considerations; and implementation of progressive regulatory strategies including early adoption of advanced manufacturing technology platforms and collaborative agency review initiatives. Notably, his impact on the development of ICH guidelines, such as ICH M13 and ICH M9 showcase his commitment to harmonizing global development practices. Dr. Bandi's contributions are further evidenced by his sustained service to AAPS and DIA, where he fosters knowledge exchange and leadership development. He is currently the Global Head and Vice President of Regulatory Affairs CMC at Astellas.

Yi Gao, Ph.D., FAAPS
Yi Gao, Ph.D., Research Fellow at AbbVie, is recognized for her work in the advancement of the fundamental understanding of amorphous solids and solid dispersions. She has also been involved with innovations in dissolution testing of products that millions of patients around the world depend upon.

Wenlei Jiang, Ph.D., FAAPS
Wenlei Jiang, Ph.D., is recognized for her creative and outstanding work in regulatory policy development related to generic drugs, and her commitment to regulatory scientific excellence and innovation in support of public health in her role as Senior Advisor for Innovation and Strategic Outreach with the U.S. FDA.

Steven R. Little, Ph.D., FAAPS
Steven R. Little, Ph.D., is the George M. and Eva M. Bevier Endowed Chair of the Department of Chemical Engineering at the University of Pittsburgh. He is recognized for his extraordinary scholarship and expertise in the field of controlled release mechanisms of drug delivery, permitting targeted delivery to inaccessible tissues.

Juliane Nguyen, Ph.D., Pharm.D., FAAPS
Juliane Nguyen, Ph.D., Pharm.D. is recognized for her pioneering efforts in developing products and therapies in the fields of targeted drug delivery and complex biotherapeutics using novel biomaterials. She is a Professor with the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill.

Jayachandra Babu Ramapuram, Ph.D., FAAPS
Jayachandra Babu Ramapuram, Professor of Pharmaceutics at the Harrison College of Pharmacy, Auburn University, is recognized for his contributions to enhancement of drug solubility, including applications to ocular, nasal and transdermal drug delivery. His work has supported the development of innovative products in both human and animal health.

Catherine Mary Turner Sherwin, Ph.D., FAAPS
Catherine Mary Turner Sherwin is recognized for her innovative application of clinical pharmacology principles to the optimization of drug treatment of children, including neonates—the world’s smallest patients. She is Vice President Clinical Pharmacology and Pharmacometrics at Differentia Bio.

Qi Tony Zhou, Ph.D., FAAPS
Qi Tony Zhou, Ph.D., Associate Professor at Purdue University, is recognized for his innovations in the formulation and manufacturing of pharmaceutical solids, leading to improvements in biologics and antibiotic formulations, leading to potentially life-saving medications.

These new AAPS Fellows will be recognized at the 2024 PharmSci 360 in Salt Lake City, Utah, on Oct. 20, at the Salt Palace Convention Center. For more information about this event or to register, visit http://www.aaps.org/pharmsci360.

About AAPS
American Association of Pharmaceutical Scientists (AAPS) is a 501(c)(3) non-profit association of more than 7,000 scientists and professionals employed in academia, industry, regulatory, and other research related to the pharmaceutical sciences worldwide. Its mission is to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health, which members pursue through four peer-reviewed journals and a variety of events in person and online. Visit: www.aaps.org/home.